Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer Pivotal Phase 3 trial recruiting 100 patients, and examining complete response of tumors as the primary endpoint. Consists of induction and maintenance phases, with follow up 12 months post...

Steba Biotech receives FDA Orphan Drug Designation for Padeliporfin ImPACT in Upper Tract Urothelial Cancer Designation confers advantages including marketing exclusivity and tax credits Padeliporfin ImPACT pivotal Phase 3 trial in UTUC to start end Q1 2021 LUXEMBOURG, March 08, 2021 (GLOBE NEWSWIRE) --...